372 related articles for article (PubMed ID: 29636357)
1. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
2. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
3. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
Pan D; Kocherginsky M; Conzen SD
Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
[TBL] [Abstract][Full Text] [Related]
4. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
5. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
7. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
[TBL] [Abstract][Full Text] [Related]
8. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
9. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
10. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
[No Abstract] [Full Text] [Related]
12. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
13. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.
Shi W; Wang D; Yuan X; Liu Y; Guo X; Li J; Song J
J Mol Cell Biol; 2019 Dec; 11(12):1042-1055. PubMed ID: 30726932
[TBL] [Abstract][Full Text] [Related]
16. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
Yau C; Benz CC
Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.
Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A
Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598
[TBL] [Abstract][Full Text] [Related]
18. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
19. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
[TBL] [Abstract][Full Text] [Related]
20. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]